WO2021197381A1 - 具有免疫调节功能的CpG ODN及其应用 - Google Patents

具有免疫调节功能的CpG ODN及其应用 Download PDF

Info

Publication number
WO2021197381A1
WO2021197381A1 PCT/CN2021/084467 CN2021084467W WO2021197381A1 WO 2021197381 A1 WO2021197381 A1 WO 2021197381A1 CN 2021084467 W CN2021084467 W CN 2021084467W WO 2021197381 A1 WO2021197381 A1 WO 2021197381A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
cpg odn
immunomodulatory
cells
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/084467
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
王立公
邵彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Huapu Parr Bio Pharmaceuticals Co ltd
Original Assignee
Nanjing Huapu Parr Bio Pharmaceuticals Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Huapu Parr Bio Pharmaceuticals Co ltd filed Critical Nanjing Huapu Parr Bio Pharmaceuticals Co ltd
Priority to US17/915,805 priority Critical patent/US12600973B2/en
Priority to CN202180019364.2A priority patent/CN115413298A/zh
Priority to JP2022559536A priority patent/JP7777874B2/ja
Priority to EP21778756.3A priority patent/EP4130268A4/en
Publication of WO2021197381A1 publication Critical patent/WO2021197381A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to an immunomodulatory CpG ODN and a composition thereof.
  • the CpG ODN has good immunostimulatory activity, can stimulate B cell proliferation and produce cytokines, can be used as a vaccine adjuvant either alone or in combination with other adjuvants to exert a synergistic effect, and can also be used in preparation for prevention or treatment Drugs for tumors, infections, and allergies.
  • BCG BCG vaccine
  • any immunologically active oligodeoxynucleotide (ODN) sequence contains at least one or more CG dinucleotides, because CG is connected by phosphorus (p), so this oligodeoxynucleotide (ODN)
  • the nucleotide sequence is collectively called CpG oligodeoxynucleotide (CpG ODN), and it is also called immune activation sequence (ISS).
  • CpG ODN The immunostimulatory activity of CpG ODN is affected by its own structural characteristics. In the genomes of pathogenic microorganisms such as bacteria, there are many CG dinucleotides, but in human and vertebrate genomes, CG dinucleotides rarely appear, and even if they do, cytosine and guanine nucleotides They are usually methylated. The deletion and reversal of CpG dinucleotides and the methylation of cytosine can lead to the loss of its activity, indicating that the existence of unmethylated CpG dinucleotides in CpG ODN is the basis of its immunostimulatory activity (Ling Shigan.
  • CpG ODN is a regular arrangement of multiple deoxynucleotides, and their combinations are diverse.
  • the immunological activity of CpG ODN with different sequence structural characteristics is very different, and changing one or a few nucleotides in the sequence may greatly affect its immunological activity. Therefore, understanding and mastering its structure-activity relationship will help us design more immunologically active sequences.
  • the CpG dinucleotide near the 5'end is C or G, it can obviously inhibit the activity of NK lymphocytes stimulated by ODN in mice, while the CpG dinucleotide near the 3'end has little effect on the activity.
  • GACGTT/C with GA at the 5'end is a CpG motif that has a strong effect on mice, but after changing to GC or GG to form a GCCGTT/C or GGCGTT/C motif, its immune activity is reduced.
  • Human peripheral blood mononuclear cells can be activated by motifs containing "GTCGTT", "TTCGTT", or "AACGTT". The most powerful motif is GTCGTT (Ballas ZK, Rasmussen W L, Krieg AM.
  • TCG repetitive sequences help to enhance the stimulating effect of CpG ODN on human B cells and NK cells (Hartmann G, Krieg AM.Mechanism and function of a newly identified CpG DNA motif in human primary B cells[J].JImmunol, 2000, 164(2):944-953).
  • TCG repeat sequences form the GTCGTC motif, indicating that the GTCGTC motif formed when the 3'end of the CpG dinucleotide is TpC also has strong immunostimulatory activity on humans (Xu Honglin, Wang Siqing, Wang Shifeng. Two CpG groups Sequence can highly activate human immune cells[J]. Chinese Journal of Microbiology and Immunology, 2001, 21(5):471-475).
  • the CpG ODN sequence has two or more copies of the 5'-NTCGTT-3' motif, and the length is 15-35 nucleotides, and N does not represent A or G. This type of CpG ODN has good immunostimulatory activity on human and mouse immune cells in vitro (Xu Honglin.
  • CpG ODN Thio-oligodeoxynucleotides with immunostimulatory activity and their applications, CN 101492672A).
  • the core sequence of CpG ODN is a 6-nucleotide motif, the general formula is: 5'-X1-X2-CG-Y1-Y2-3', where X1 is purine nucleotide (purine), X2 is also It is purine or thymine (T), Y1 and Y2 are pyrimidines.
  • the surrounding sequence and the sequence between multiple CpGs also have an impact on the activity of CpG ODN (Krieg AM, Hartmann G, Yi AK. Mechanism of action of CpG DN A.
  • TLR 9 is a member of the Toll-like receptors (TLRs) family and mainly recognizes the CpG motif of bacterial DNA.
  • CpG ODN can stimulate the body's innate immune response in a TLR 9-dependent manner.
  • CpG ODN in viral and bacterial genomes is a natural agonist of TLR9, so once cells infect or ingest bacteria, TLR9 will initiate a Th1-type dominant immune response (AHLERS J D, BELYAKOV I M. Memories that last forever: Strategies for optimizing vaccine T-cell memory[J]Blood,2010,115(9); 1678-1689).
  • CpG ODN can not only stimulate cells expressing TLR 9 molecules, trigger an immune regulatory cascade, and ultimately produce pro-inflammatory cytokines and chemokines, but can also improve the antigen presentation function of dendritic cells, monocytes and macrophages, and induce The proliferation of B cells stimulates the immune protective activity of NK cells and induces the immune response in the body. It is a highly effective and low-toxic immune adjuvant and has a strong application value in the treatment of diseases (SUN S Q, ZHANG X H, TOUGH D F. Type I interferon-mediated stimulation of T cells by CpG DNA [J] J. Exp Med, 1998, 188(12): 2335-2342).
  • CpG ODN The vaccine adjuvant activity of CpG ODN has been verified in a large number of animal experiments of preventive and therapeutic vaccines.
  • KRIEG AM Therapeutic potential of Toll-like receptor 9 activation[J].
  • Type B CpG ODN is the main research object of the experiment. It is used as a vaccine adjuvant to prevent and treat infectious diseases. Among them, Dynavax's HEPLISAV-B hepatitis B vaccine was approved by the FDA in November 2017.
  • CpG ODN has anti-tumor activity in many mouse models.
  • CpG ODN alone can effectively induce T cell-mediated tumor rejection.
  • other treatment methods such as monoclonal antibodies, radiotherapy, surgery, and chemotherapy, will have a strong synergistic effect.
  • CpG ODN-mediated tumor regression can be T cell dependent, NK cell independent, NK cell dependent, T cell independent.
  • CpG 7909 can significantly improve the survival status of tumor patients, and can induce a stronger CD8+ T cell response specific to melanoma protein antigen (van Ojik, H.et al Phase I/II study with CPG 7909 as adjuvant to vaccination with MAGA-3 Protein in Patients with MAGA-3 Positive tumors.Ann Oncol 2002,13, 157; thoughr,DEet al.Rapid and strong human CD8(+)Ttocell vaccination response with peptide, IFA, and CPG oligodeoxynucleotide 7909.J Clin Invest, 2005, 115, 739-746).
  • CpG ODN alone or in combination with anti-tumor antibodies can induce the secretion of Th1 cytokines and enhance the role of ADCC (Hartmann, E. et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003: 63,6478-6487).
  • B type 1018 ISS combined with rituximab in the treatment of non-Hodgkin’s lymphoma is very effective and has entered clinical trials (Friedberg, JWet al.
  • CpG ODN is a high-efficiency and low-toxicity immune adjuvant, which has strong potential application value in the treatment of infectious diseases, immunodeficiency diseases, tumors, and allergic diseases.
  • the current practical application is limited, and more and more in-depth studies are needed to design more and more effective sequence structures, so that they can play their potential more widely and be applied in clinics more safely and efficiently.
  • the present invention provides a series of CpG ODN with immune regulation function.
  • the structure of these CpG ODNs is novel, and what is even more rare is that they have immunostimulatory effects on mice and humans, so they have great clinical application value.
  • the present invention solves the problems existing in the field through the following technical solutions:
  • An immunomodulatory CpG ODN which comprises or consists of a nucleotide sequence selected from SEQ ID NO: 1-6, wherein at least one nucleotide in the nucleotide sequence has the general formula I Structure of chemically modified nucleotides:
  • Y is S or O
  • R is H or a positively charged counterion
  • B is independently an unmodified or modified nucleobase
  • R 1 is H, F, Cl, OH, OMe, Me, O- Ethyloxymethyl.
  • the immunomodulatory CpG ODN as described in item 3 its sequence is: SEQ ID NO: 1-6, preferably all phosphorothioate SEQ ID NO: 1-6, more preferably all sulfur The phosphorylated SEQ ID NO: 3 or 6.
  • a pharmaceutical composition comprising the immunomodulatory CpG ODN described in any one of items 1 to 4 and a pharmaceutically acceptable carrier.
  • the amount of CpG ODN is 0.01 ⁇ g-1000 ⁇ g/ml, more preferably 1-10 ⁇ g/ml, for example, 1, 3, or 10 ⁇ g/ml.
  • the vaccine adjuvant further comprises one or more other adjuvants that work together with the immunomodulatory CpG ODN, such as insoluble aluminum salt colloids, Oil and water emulsions, microorganisms and metabolites, nucleic acids and their analogs, cytokines, immunostimulatory complexes, propolis, and liposomes.
  • adjuvants such as insoluble aluminum salt colloids, Oil and water emulsions, microorganisms and metabolites, nucleic acids and their analogs, cytokines, immunostimulatory complexes, propolis, and liposomes.
  • a vaccine comprising the immunomodulatory CpG ODN according to any one of items 1 to 4 and an antigen, wherein the antigen is a rabies antigen or a new coronary pneumonia antigen.
  • the dosage of the CpG ODN is 0.01 ⁇ g-1000 ⁇ g/ml, more preferably 1-10 ⁇ g/ml, for example, 1, 3, or 10 ⁇ g/ml.
  • the vaccine is a new coronary pneumonia vaccine, preferably a new coronary pneumonia inactivated vaccine, wherein the vaccine further comprises an aluminum adjuvant, such as an aluminum hydroxide adjuvant.
  • Figure 1 shows the effect of CpG ODN on the proliferation of mouse spleen T and B cells.
  • Figure 2 shows that CpG ODN stimulates mouse spleen cells to produce cytokine IFN- ⁇ .
  • Figure 3 shows the effect of CpG ODN in stimulating mouse splenocytes to produce cytokine IL-6.
  • Figure 4 shows that CpG ODN stimulates mouse splenocytes to produce cytokine TNF- ⁇ .
  • Figure 5 shows the effect of CpG ODN on the proliferation of human PBMCs T and B cells.
  • Figure 6 shows that CpG ODN stimulates the secretion of IFN- ⁇ from human PBMCs.
  • Figure 7 shows that CpG ODN stimulates IL-6 secretion in human PBMCs.
  • Figure 8 shows that CpG ODN stimulates the secretion of TNF- ⁇ from human PBMCs.
  • Figure 9 shows the detection results of HEK-Blue hTLR9 cells stimulated by CpG.
  • Figure 10 shows the detection results of HEK-Blue mTLR9 cells stimulated by CpG.
  • FIG. 11 shows the results of CpG stimulated Ramos-Blue cells.
  • Figure 12 shows the effect of ODN3 on rabies virus neutralizing antibody titers.
  • Figure 13 shows the immune synergistic effects of different doses of ODN3 and rabies vaccine combination.
  • Figure 14 shows the immune synergism of the combination of different doses of rabies vaccine and ODN3.
  • Figure 15 shows the effects of different combinations of CpG ODN and rabies vaccine on rabies virus neutralizing antibody titers.
  • Figure 16 shows the effect of the combined use of ODN6 and inactivated new coronary pneumonia vaccine on mouse anti-SARS-CoV-2 S protein-specific IgG antibody titers on D6-28.
  • Figure 17 shows the effect of the combined use of ODN6 and the inactivated new coronary pneumonia vaccine on the titers of mouse anti-SARS-CoV-2 S protein-specific IgG antibodies on D28.
  • Figure 18 shows the effect of the combined use of ODN6 and inactivated new coronary pneumonia vaccine on mouse anti-SARS-CoV-2 neutralizing antibody titers on D28.
  • the CpG ODN described in the present invention is a non-methylated dinucleotide connected by phosphodiester bonds and has an immunostimulatory effect.
  • CpG ODN can promote the proliferation and differentiation of B cells and secrete IL-6, thereby inducing the secretion of antibodies; activate monocytes, macrophages, dendritic cells and other presenting cells to secrete a variety of cytokines (for example, IL-12, IL) -6, TNF- ⁇ , IFN- ⁇ and IFN- ⁇ etc.).
  • Cytokines indirectly promote the activity of killer T cells (CTL) and natural killer cells (NK cells), induce intracellular pathogens to produce cellular immunity, and induce NK cells and T cells to secrete IFN- ⁇ .
  • CTL killer T cells
  • NK cells natural killer cells
  • CpG ODN can also enhance antigen-specific response, which is due to (1) there is a strong relationship between the signal transduction pathway triggered by the B cell antigen receptor and the B cell signal transduction pathway triggered by CpG Synergistic effect; (2) Th1-like cytokines that can increase antigen-specific T helper, thereby enhancing the antigen-specific response of B cells and T cells, and (3) the cell response needs to be positively regulated by costimulatory molecules.
  • the CpG motif is the basic structure of CpG ODN to produce immunostimulatory effects. It is composed of CpG dinucleotides and two bases each at the 5'end and 3'end.
  • the number of CpG motifs contained in the ODN is usually 2-4 CpG motifs.
  • the spacing between CpG motifs is usually at least two bases apart, and thymine is preferred.
  • CpG ODN containing poly-G sequence (consisting of 3 or more guanines) has a strong effect of stimulating plasmacytoid dendritic cells (pDC) to produce interferon- ⁇ ; all thio-modified CpG ODN is the most stable , And has the best stimulating effect on B cells, but all thio-modified CpG ODN stimulates pDC to produce IFN- ⁇ , but it is not as good as partially thio-modified CpG ODN.
  • pDC plasmacytoid dendritic cells
  • CpG ODN can be divided into three types (Tomoki Ito, et al., Blood, 2006, Vol 107, Num6: 2423-2431):
  • Type A CpG ODN synthesized by a chimeric skeleton, where the 5'and 3'ends of the skeleton are phosphorothioate, and the middle CpG region is a phosphodiester.
  • These ODNs can well activate natural killer cells (NK cells).
  • NK cells natural killer cells
  • pDC cells plasmacytoid dendritic cells
  • Type B CpG ODN through the synthesis of phosphorothioate backbone that can resist nucleases, it can well activate B cells and pDC cells to produce IL-12 and induce antibody secretion, but it can only activate NK cells to a limited extent. , Usually type B CpG ODN can be effectively used as a vaccine adjuvant; and
  • Type C CpG ODN synthesized through the phosphorothioate backbone, has a stimulating activity between Type A and Type B CpG ODN. For example, it can well activate B cells, and it can also activate NK cells and NK cells. pDC cells.
  • the immunomodulatory CpG ODN used in the present invention comprises or consists of a nucleotide sequence selected from SEQ ID NO: 1-6, wherein at least one nucleotide in the nucleotide sequence has a structure represented by Formula I
  • Y is S or O, especially S, R is H or a positively charged counterion
  • B is independently an unmodified or modified nucleobase
  • R 1 is H, F, Cl, OH, OMe, Me, O-Ethyloxymethyl.
  • Me represents a methyl group.
  • the bases in the CpG ODN of the present invention may be unmodified, partially modified, or fully modified nucleobases (natural nucleobases include adenine, guanine, cytosine and thymine).
  • the backbone modification of the CpG ODN may include using phosphorothioate to partially modify or completely modify the bases in the CpG ODN of the present invention.
  • the modification can be carried out during the synthesis of the oligonucleotide or after synthesis, and the modification can occur on the phosphodiester bridge between the nucleosides, on the ribose unit and/or the natural nucleobase ( That is, adenine, guanine, cytosine and thymine).
  • the modified base can be incorporated into the oligonucleotide or located at the end of the oligonucleotide.
  • the modification can be performed by using an active group, for example, by an amino modification component, by a 3'or 5'hydroxyl group, or by a phosphate group.
  • the chemical modification of the present invention may include modifying the backbone of the CpG ODN of the present invention, including but not limited to, modifying the backbone with phosphorothioate to obtain a phosphorothioate backbone, which is a stable nucleic acid
  • the sugar phosphate backbone of the molecule in which sulfur replaces the oxygen of the unbridged phosphate at the bond between at least one nucleotide, or the bond between every or every other nucleotide Above, sulfur replaces the oxygen of the unbridged phosphate ester.
  • oligonucleotide backbone for example, the use of non-ionic DNA analogues, such as alkyl phosphate and aryl phosphate, to modify the backbone, in which alkyl or aryl substitutions are charged
  • non-ionic DNA analogues such as alkyl phosphate and aryl phosphate
  • the oxygen in the phosphoric acid ester or the use of phosphoric acid diester and alkyl phosphoric acid triester to modify the backbone, in which the charged oxygen is alkylated.
  • the immunomodulatory CpG ODN of the present invention has a novel sequence structure, and it is more rare that it has an immunostimulatory effect on mice and humans, so it has great clinical application value.
  • sequence of the immunomodulatory CpG ODN of the present invention is ODN3 or ODN6, which comprises at least one chemically modified nucleotide having the structure shown in general formula I, wherein the substituent of the general formula The group is as defined above.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the immunomodulatory CpG ODN described herein and a pharmaceutically acceptable carrier.
  • “Pharmaceutically acceptable carrier” refers to ingredients other than the active ingredient in the pharmaceutical preparation, which are non-toxic to the subject.
  • Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.
  • subject used in the present invention refers to animals, including, but not limited to, primates (for example, humans), cows, sheep, goats, horses, dogs, pigs, cats, rabbits, rats, small animals Rats, fish, birds, such as poultry, such as chickens, ducks, geese, etc.
  • animal is a mammal.
  • subject is a human.
  • Immune cells in the present invention refer to all cells involved in and related to immune responses and their precursor cells.
  • Immune cells include T cells (for example, CD4+ cells, CD8+ cells and various other T cell subtypes), B cells (Eg CD19), natural killer cells (NK cells), macrophages, monocytes, dendritic cells and neutrophils.
  • T cells for example, CD4+ cells, CD8+ cells and various other T cell subtypes
  • B cells Eg CD19
  • natural killer cells NK cells
  • macrophages monocytes, dendritic cells and neutrophils.
  • T lymphocytes and specific B lymphocytes expressing specific antigen receptors are involved in mediating adaptive immune responses.
  • B lymphocytes can activate, proliferate and differentiate into plasma cells after receiving antigen-specific stimulation, produce specific antibodies, and mediate fluid immune responses;
  • T lymphocytes can activate, proliferate and differentiate into effector T cells after receiving antigen-specific stimulation.
  • full-time APCs such as dendritic cells and monocytes are involved to present antigens to activate T cells; in the effect phase of the acquired immune response, monocytes, macrophages and NK cells Participate and cooperate with T cells, antibodies, etc. to play the role of eliminating antigens.
  • the cells involved in the innate immune response mainly include monocytes, macrophages, granulocytes, dendritic cells, NK cells, endothelial cells, mast cells, red blood cells, platelets, etc., as well as a small number of T and B lymphocyte subgroups.
  • NK cells are the third type of lymphocytes, which have non-specific cytotoxic activity and play an important role in the innate immune response to anti-viral infection and anti-tumor.
  • Monocytes, macrophages, granulocytes, etc. have strong phagocytosis and killing functions, and participate in the inflammatory response by releasing a large amount of active products.
  • the synergistic effect of the antigen of the present invention and CpG ODN simultaneously induces humoral immune response and cellular immune response, strengthens Th1 type T cell immune function, and greatly enhances T cell immune response.
  • the "vaccine” of the present invention is a vaccine well-known to those of ordinary skill in the art. It generally refers to any vaccine that can induce the body to produce specific antibodies and/or cellular immunity against specific pathogens after inoculation by injection or mucosal route, so that the body can obtain Biological products with the ability to protect or eliminate the pathogen, including proteins, polysaccharides, nucleic acids, live vectors or infectious agents, etc.
  • Vaccines are autoimmune preparations made from pathogenic microorganisms (such as bacteria, rickettsiae, viruses, etc.) and their metabolites through artificial attenuation, inactivation, or genetic engineering methods to prevent infectious diseases. The vaccine retains the characteristics of pathogenic bacteria that stimulate the animal's immune system.
  • the immune system When the animal body comes into contact with this innocuous pathogen, the immune system will produce certain protective substances, such as immune hormones, active physiological substances, special antibodies, etc.; when the animal comes into contact with this pathogen again, the animal’s immunity The system will follow its original memory and create more protective substances to prevent pathogenic bacteria from harming.
  • the "vaccine” in the present invention refers to a preparation designed to induce an immune response against an antigen.
  • Vaccines can be therapeutic, in which they are given during treatment to boost the immune response or drive a response in a specific direction, or vaccines can be prophylactic, and they can be given before or immediately after the onset of the disease.
  • Vaccines can be both curative and preventive at the same time in terms of treating existing diseases and preventing diseases that will relapse in the future.
  • the vaccine can be administered to the subject by the administration method commonly used in the art.
  • administration or “administration” as used herein includes all suitable ways of providing a substance to a patient. Common routes include oral, sublingual, transmucosal, transdermal, rectal, vaginal, subcutaneous, intramuscular, intravenous, intraarterial, sheath Internal administration, administration through a catheter, administration through an implant, etc.
  • the antigen of the present invention can be used to prepare drugs for inducing an immune response in a subject against the antigen.
  • the antigen of the present invention can be used to prepare a rabies vaccine.
  • the antigen of the present invention can be used to prepare animal and human rabies vaccines.
  • Rabies vaccines for animals include inactivated vaccines, attenuated vaccines and genetic engineering vaccines.
  • Human rabies vaccines include nerve tissue-derived vaccines, poultry embryo culture vaccines, cell culture vaccines, subunit and refined vaccines, genetic engineering vaccines, etc.
  • the antigen of the present invention can be used to prepare a new crown vaccine.
  • the "vaccine adjuvant” or “adjuvant” of the present invention is a vaccine adjuvant well known to those of ordinary skill in the art.
  • the word adjuvant originated from the Latin “Aduvare”, which means supplement or enhancement.
  • Vaccine adjuvant is an additive of vaccine. When it is injected into the body before or mixed with antigen, it can enhance the body's immune response to antigen or change the type of immune response. It is a non-specific immune enhancer, and it does not itself Antigenicity.
  • adjuvants mainly include insoluble aluminum salt colloids, oil-water emulsions, microorganisms and metabolites, nucleic acids and their analogs, cytokines, immunostimulatory complexes, propolis, Liposomes and so on.
  • the immunomodulatory CpG ODN of the present invention can also be used as a vaccine adjuvant, and can exert an excellent adjuvant function.
  • the immunomodulatory CpG ODN of the present invention can be used alone as an adjuvant for a vaccine (such as a rabies vaccine or a new crown vaccine), or combined with other commonly used adjuvants as an adjuvant for a vaccine (such as a rabies vaccine or a new crown vaccine).
  • the immunomodulatory CpG ODN and these commonly used adjuvants can play an additive or synergistic effect to improve the immunogenicity of the antigen, thereby reducing the amount of vaccine or improving the effect of the vaccine (such as reducing the dose of the vaccine or reducing the number of times of vaccine administration) . Therefore, in one embodiment, the present invention also provides the use of the immunomodulatory CpG ODN described herein in preparing a vaccine adjuvant.
  • the vaccine is a rabies vaccine or a new crown vaccine.
  • the vaccine adjuvant described herein further includes one or more other substances that play an adjuvant effect together with the immunomodulatory CpG ODN.
  • the effective amount of the immunomodulatory CpG ODN described herein can be determined by those skilled in the art through routine experiments, for example, the effective amount can be 0.01 ⁇ g-1000 ⁇ g/ml Vaccine, including any value in the range of 0.01 ⁇ g-1000 ⁇ g/ml, for example, 0.1 ⁇ g/ml, 0.2 ⁇ g/ml, 0.3 ⁇ g/ml, 0.4 ⁇ g/ml, 0.5 ⁇ g/ml, 0.6 ⁇ g/ml, 0.7 ⁇ g/ ml, 0.8 ⁇ g/ml, 0.9 ⁇ g/ml, 1.0 ⁇ g/ml, 1.1 ⁇ g/ml, 1.2 ⁇ g/ml, 1.3 ⁇
  • this article refers to a preparation that is effective in such a form to allow the biological activity of the active ingredient contained therein, and which does not affect the subject to which the preparation will be administered. An additional component of unacceptable toxicity.
  • this article relates to the use of the immunomodulatory CpG ODN or the pharmaceutical composition described herein in the preparation of a medicament for preventing or treating tumors, microbial infections or allergies in a subject.
  • the subject is a human or animal, such as mice, rats, domestic animals, such as dogs, pigs, cattle, horses, and poultry, such as chickens, ducks, and geese.
  • Those skilled in the art can determine the effective amount of the immunomodulatory CpG ODN in the drug or pharmaceutical preparation according to conventional methods, and determine the administration method of the drug according to conventional methods.
  • ODN 1 5'-tcgcgacgttcgcgggacgttcccta-3', SEQ ID NO:1)
  • ODN2 5'-tcgcgacgttcgcgcgacgttcgcta-3', SEQ ID NO: 2
  • ODN3 5'-tcgcgacgttcgta-3', SEQ ID NO: 1) :3)
  • ODN4 5'-tggacgttcgtcgttcgtccttc-3', SEQ ID NO: 4
  • ODN5 5'-tcgtcgttcgtcgttcgacgttc-3', SEQ ID NO: 5
  • ODN6 5'-tcgaggttcgtcgttcctcgtc-3', SEQ ID NO:
  • HP3004 is the positive control CpG ODN (5'-tgactgtgaacgttcgagatga-3', SEQ ID NO: 7, all phosphorothioate)
  • HP0000 is the negative control CpG ODN (5'-tggccaagcttgggccccttgcaagggcc-3', SEQ ID NO: 8, All phosphorothioate). All CpG ODN was dissolved in sterile/endotoxin-free water (InvivoGen, USA) and stored at -40°C for later use.
  • Rabies vaccine taken from the Changchun Biological Products (Vero cell rabies vaccine) / Chengdu Kang Huasheng Biological Products Co., Ltd. (human diploid cell rabies vaccine).
  • the new crown vaccine inactivated vaccine was provided by Zhejiang Tianyuan Biological Pharmaceutical Co., Ltd.
  • Human peripheral blood leukocyte concentrates were purchased from Changchun City Center Blood Station.
  • Female BALB/c mice aged 6-8 weeks were purchased from Changchun Institute of Biological Products Co., Ltd.
  • PBMCs peripheral blood mononuclear cells
  • 5’-DMT dA, dG, dC, dT and other phosphoramidite monomers were purchased from Shanghai Zhaowei Technology Development Co., Ltd.
  • the corresponding vector was purchased from Chemgenes (Wilmington, MA).
  • the 2'-substituted ribonucleoside phosphoramidite was purchased from Shanghai Zhaowei Technology Development Co., Ltd., Promega (Obispo, CA).
  • Example 2 The effect of CpG ODN on the proliferation of mouse spleen cells T and B cells
  • mice spleen under aseptic conditions prepare BALB/c mouse spleen cell suspension after grinding and filtering, use RPMI-1640 complete medium to suspend the cells, and spread 5 ⁇ 10 5 or 1 ⁇ 10 6 /well in 96 wells To the U-shaped plate, add different concentrations of CpG (0.03, 0.1, 0.3, 1 and 3 ⁇ M), and place them in a 37°C, 5% CO 2 incubator.
  • the cells were collected, washed twice with 1 ⁇ PBS, and centrifuged at 1500 rpm for 5 min. Resuspend the cells with 1 ⁇ PBS, add anti-CD4, anti-CD8 and anti-CD19 antibodies (BD, USA) to the cell suspension, and incubate for 30 min at 4°C in the dark. Washed twice with 1 ⁇ PBS, centrifuged at 1500 rpm for 5 min, resuspended cells in 1 ⁇ PBS, and analyzed flow cytometry using BD LSRFortessa TM flow cytometer (BD, USA).
  • the supernatant was collected for ELISA analysis.
  • the level of CD4, CD8, and CD19 in the supernatant was measured by sandwich ELISA, and the effect of CpG ODN on the proliferation of mouse spleen cells T and B cells was obtained.
  • the measurement results are shown in Figure 1.
  • CpG ODN can greatly stimulate mouse spleen B cell activation (reflected by CD19 level), induce mouse spleen B cell proliferation, and then up-regulate the expression of costimulatory molecules and secrete cytokines (such as IL-6, TNF- ⁇ ) .
  • costimulatory molecules and secrete cytokines such as IL-6, TNF- ⁇
  • Spleen cells from 4-8 weeks old C57BL/6 were prepared and cultured in RPMI complete medium.
  • the mouse spleen cells were seeded in a 24-well culture dish at 5 ⁇ 10 6 cells/ml.
  • CpG ODN dissolved in PBS buffer was added to the cell culture to a final concentration of 0.03, 0.1, 0.3, 1 and 3 ⁇ M, respectively.
  • the cells were then incubated at 37°C for 24h, and the supernatant was collected for ELISA analysis.
  • the levels of IFN- ⁇ , IL-6 and TNF- ⁇ in the supernatant were measured by sandwich ELISA.
  • the required reagents, including cytokine antibodies and standards, were purchased from BD PharMingen. The measurement results are shown in Figures 2, 3 and 4.
  • Figure 2 shows that different CpG ODNs effectively stimulate pDC to secrete IFN- ⁇ levels, and HP3004 is the positive control.
  • Figure 3 shows that different CpG ODN stimulated B cells to produce IL-6 levels, and HP3004 was the positive control.
  • Figure 4 shows that different CpG ODN stimulated B cells to produce TNF- ⁇ levels, and HP3004 was the positive control.
  • Example 4 The effect of CpG ODN on the proliferation of T and B cells induced by human PBMC
  • composition of the medium used for analysis was RPMI1640 medium supplemented with 1.5mM glutamine, 1mM sodium pyruvate, 0.1mM non-essential amino acids, 50 ⁇ M 2-mercaptoethanol, 100IU/ml penicillin-streptomycin mixture and 10% Heat-inactivated fetal bovine serum.
  • RPMI1640 medium supplemented with 1.5mM glutamine, 1mM sodium pyruvate, 0.1mM non-essential amino acids, 50 ⁇ M 2-mercaptoethanol, 100IU/ml penicillin-streptomycin mixture and 10% Heat-inactivated fetal bovine serum.
  • a total of 0.5 ⁇ 10 6 B cells per ml ie 0.1 ⁇ 10 6 /200 ⁇ l/well
  • CpG ODN 0.03, 0.1, 0.3, 1 and 3 ⁇ M
  • the plates were harvested using a cell harvester, and the radioactive incorporation was measured using standard liquid scintillation techniques. The results are expressed as average cpm+/-SD or proliferation index (cpm treatment group/cpm medium control). The results of the determination are shown in Figure 5, where HP3004 is the positive control.
  • CpG ODN can activate human PBMC cells, induce B cell proliferation, and then up-regulate the expression of costimulatory molecules and secrete cytokines (such as IL-6, TNF- ⁇ ).
  • cytokines such as IL-6, TNF- ⁇ .
  • Human PBMC was seeded in 96-well plates at 5 ⁇ 10 6 cells/ml.
  • CpG ODN dissolved in phosphate buffer (PBS, pH 7.4; Mediatech) was added to the cell culture to a final concentration of 10.0 ⁇ g/ml.
  • PBS phosphate buffer
  • the cells were then incubated at 37°C for 24h, and the supernatant was collected for ELISA analysis. Each experiment was repeated in 3 wells.
  • the levels of IFN- ⁇ , IL-6 and TNF- ⁇ were measured by sandwich ELISA.
  • the required reagents, including cytokine antibodies and standards, were purchased from PharMingen. The measurement results are shown in Figure 6-8.
  • CpG ODN sequence can greatly increase IL-6 and TNF- ⁇ levels.
  • the cells were maintained and subcultured in a proliferation medium supplemented with 10 ⁇ g/ml blasticidin and 100 ⁇ g/ml Zeocin TM.
  • Proliferation medium DMEM, 4.5g/L glucose, 10% (v/v) fetal bovine serum, 50U/ml penicillin, 50U/ml streptomycin, 100 ⁇ g/ml Normocin TM , 2mM-glutamine.
  • the cells When the density reaches 70%-80%, the cells should be passaged. After replacing the original medium with PBS, the cells can be separated by tapping the flask or using a cell scraper. The separated cells were collected and centrifuged for 5 min. Count the cells, plant 2-4 ⁇ 10 4 cells in a 96-well plate, and add medicine 2-3 days later.
  • the default final concentrations of the positive control (HP3004), negative control (HP0000) and CpG ODN are 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 ⁇ g/ml, and the concentration of the medium is different Less than 90%.
  • Example 7 The effect of combined use of ODN3 and rabies vaccine on mouse anti-rabies virus neutralizing antibody titers
  • mice were divided into 8 groups, each with 8 mice.
  • the background serum of a group of mice was collected 2 days before immunization.
  • the time of vaccine injection (intramuscular injection) was: 0, 3, and 7 days;
  • the eyeballs were removed and the blood was collected, the serum was separated, and the titers of the neutralizing antibodies against rabies virus in the mouse serum were determined one by one using the RFFIT method.
  • the measurement results are shown in Figure 12.
  • mice Take 112 mice, half female and half male, weighing 18-22 grams, rabies vaccine: 1ml/vessel (containing 2.5IU), ODN3.
  • Experimental grouping 8 animals in each group, half male and half female.
  • the above-mentioned rabies vaccine and CpG ODN are all dissolved in PBS.
  • mice On day 0, day 3, day 7, day 14 and day 28, mice were immunized in different groups.
  • the immunization method is intraperitoneal injection of mice. 4, 6, and 8 days after the immunization, blood was collected from the tail vein of the mice, and the serum was separated.
  • the rapid rabies vaccine fluorescent focus inhibition test (RFFIT) method was used to detect the titer of the rabies vaccine antibody in the serum of the mice. Two days before immunization, blood was taken from the tail vein of the mice, and the obtained serum was used as a negative control.
  • RFFIT rapid rabies vaccine fluorescent focus inhibition test
  • ODN3 can significantly increase the immune effect of strong rabies vaccine.
  • Example 9 ODN3 is used as a rabies vaccine adjuvant to reduce the dosage of rabies vaccine
  • mice Use 128 mice, half female and half male, weighing 18-22 grams, rabies vaccine: 1ml/vessel (containing 2.5IU).
  • Experimental grouping 8 animals in each group, half male and half female.
  • mice On day 0, day 3, day 7, day 14 and day 21, mice were immunized in different groups.
  • the immunization method is intraperitoneal injection of mice. Blood was collected from the tail vein of the mice on 28 days, the serum was separated, and the rapid rabies vaccine fluorescence focus inhibition test (RFFIT) method was used to detect the titer of the rabies vaccine antibody in the mice serum. Two days before immunization, blood was taken from the tail vein of the mice, and the obtained serum was used as a negative control.
  • RFFIT rapid rabies vaccine fluorescence focus inhibition test
  • results The combined application of rabies vaccine and ODN3 can still stimulate mice to produce higher levels of rabies virus-specific antibodies.
  • Rabies vaccine +1 ⁇ g ODN3, 1/2 rabies vaccine+1 ⁇ g ODN3, 1/4 rabies vaccine 1 ⁇ g ODN3, 1/8 rabies vaccine + 1 ⁇ g ODN3 can reach higher antibody titer (GMT) than when rabies vaccine is used alone, indicating that CpG ODN can reduce the dosage of rabies vaccine.
  • GTT antibody titer
  • ODN3 can reduce the dosage of rabies vaccine.
  • mice were randomly divided into eight groups, the human rabies vaccine group, the human rabies vaccine + ODN1 (10 ⁇ g/head) group, the human rabies vaccine + ODN2 (10 ⁇ g/head) group, the human rabies vaccine + ODN3 (10 ⁇ g) /Head) group, human rabies vaccine + ODN4 (10 ⁇ g/head) group, human rabies vaccine + ODN5 (10 ⁇ g/head) group, human rabies vaccine + ODN6 (10 ⁇ g/head) group, human rabies vaccine + HP0000
  • each group was immunized three times through hind limb muscles on the 0th, 7th, and 21st days, and the dose of each immunization was 0.2ml/mouse.
  • the eyeballs were removed on the 14, 28, and 56 days after immunization to take blood, and the serum was separated to detect the serum anti-rabies virus antibody content.
  • the neutralizing antibody titers are shown in Figure 15.
  • CpG ODN can increase the level of antibody titer.
  • Example 11 The effect of the combined use of ODN6 and the inactivated new coronary pneumonia vaccine on the titers of mouse anti-SARS-CoV-2 S protein-specific IgG and virus neutralizing antibodies
  • mice choose 18-20g BALB/c mice, 9 or 10 in each group, half male and half male; each group will immunize mice by intraperitoneal injection on D0 and D14 according to the designed immunization program, each injection of 0.5ml .
  • blood was collected at D0, D6, D13, D21, and D28 to separate the serum. All sera were tested for S protein-specific IgG and virus neutralizing antibodies; the geometric average of each group of animal serum IgG and virus neutralizing antibodies was calculated according to statistics potency. The measurement results are shown in Figure 16-18.
  • the new coronary pneumonia inactivated vaccine When the new coronary pneumonia inactivated vaccine is combined with ODN6 and aluminum adjuvant, it can induce higher SARS-CoV-2 S protein-specific IgG and virus neutralizing antibody titers as a whole.
  • the 4 ⁇ g/mL antigen+450 ⁇ g/mL aluminum hydroxide adjuvant+40 ⁇ g/mL CpG group induced the highest S1 antibody titer.
  • the 8 ⁇ g/mL antigen+450 ⁇ g/mL aluminum hydroxide adjuvant+400 ⁇ g/mL CpG group induced the highest neutralizing antibody titer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CN2021/084467 2020-04-01 2021-03-31 具有免疫调节功能的CpG ODN及其应用 Ceased WO2021197381A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/915,805 US12600973B2 (en) 2020-04-01 2021-03-31 CpG ODN having immunoregulatory function and use thereof
CN202180019364.2A CN115413298A (zh) 2020-04-01 2021-03-31 具有免疫调节功能的CpG ODN及其应用
JP2022559536A JP7777874B2 (ja) 2020-04-01 2021-03-31 免疫調節機能を有するＣｐＧ ＯＤＮ及びその使用
EP21778756.3A EP4130268A4 (en) 2020-04-01 2021-03-31 ODN CPG WITH IMMUNOREGULATORY FUNCTION AND CORRESPONDING USE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010253089.8A CN113493790A (zh) 2020-04-01 2020-04-01 具有免疫调节功能的CpG ODN及其应用
CN202010253089.8 2020-04-01

Publications (1)

Publication Number Publication Date
WO2021197381A1 true WO2021197381A1 (zh) 2021-10-07

Family

ID=77929639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/084467 Ceased WO2021197381A1 (zh) 2020-04-01 2021-03-31 具有免疫调节功能的CpG ODN及其应用

Country Status (5)

Country Link
US (1) US12600973B2 (https=)
EP (1) EP4130268A4 (https=)
JP (1) JP7777874B2 (https=)
CN (2) CN113493790A (https=)
WO (1) WO2021197381A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116064548A (zh) * 2022-12-01 2023-05-05 北京吉诺卫生物科技有限公司 一种新型CpG疫苗佐剂及其应用
EP4332225A4 (en) * 2021-04-30 2025-11-05 Parr Biotechnology Hebei Co Ltd USE OF ARTIFICIALLY SYNTHETIC CPG SINGLE-RANK DEOXYOLIGONUCLEOTIDE IN VACCINES

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN118356486A (zh) * 2023-01-19 2024-07-19 华普生物技术(河北)股份有限公司 CpG佐剂在制备新型冠状病毒疫苗中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678188A (zh) * 2002-07-03 2005-10-05 科勒制药集团有限公司 调节免疫反应的核酸成分
CN101094594A (zh) * 2003-12-08 2007-12-26 海布里顿公司 通过基于小寡核苷酸的化合物调节免疫刺激性质
CN101492672A (zh) 2008-01-23 2009-07-29 许洪林 具有免疫刺激活性的硫代寡聚脱氧核苷酸及其应用
WO2019115385A1 (en) * 2017-12-15 2019-06-20 Bayer Animal Health Gmbh Immunostimulatory compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1271733A (zh) * 2000-04-04 2000-11-01 中国预防医学科学院病毒学研究所 对人免疫细胞有特异免疫刺激活性的CpG寡核酸
US7491706B2 (en) * 2003-07-25 2009-02-17 Changchun Huapu Biotechnology Co., Ltd. Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof
PL3096786T3 (pl) * 2014-01-21 2021-11-08 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
CN105214083A (zh) * 2014-06-26 2016-01-06 长春华普生物技术有限公司 含有CpG寡核苷酸的药物组合物
JP7048102B2 (ja) * 2019-05-23 2022-04-05 国立研究開発法人医薬基盤・健康・栄養研究所 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678188A (zh) * 2002-07-03 2005-10-05 科勒制药集团有限公司 调节免疫反应的核酸成分
CN101094594A (zh) * 2003-12-08 2007-12-26 海布里顿公司 通过基于小寡核苷酸的化合物调节免疫刺激性质
CN101492672A (zh) 2008-01-23 2009-07-29 许洪林 具有免疫刺激活性的硫代寡聚脱氧核苷酸及其应用
WO2019115385A1 (en) * 2017-12-15 2019-06-20 Bayer Animal Health Gmbh Immunostimulatory compositions

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
BALLAS ZKRASMUSSEN W LKRIEG AM: "Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA", J IMMUNOL, vol. 157, no. 5, 1996, pages 1840 - 1845
CARPENTIER ALAIGLE-DONADEY FZOHAR S ET AL.: "Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma", NEURO-ONCOL, vol. 8, no. 1, 2006, pages 60 - 66
DENNIS M KLINMAN: "CpG DNA as a vaccine adjuvant", EXPERT REV VACCINES, vol. 2, no. 2, 2003, pages 305 - 315, XP009145660, DOI: 10.1586/14760584.2.2.305
FRIEDBERG, J. W. ET AL.: "Combination immunotherapy with a CPG oligonucleotide(1018 ISS) and rituximab in Patients with non-Hodgkin lymphoma: increased interferon-a/p-inducible gene expression, without significant toxicity", BLOOD, vol. 105, 2005, pages 489 - 495, XP055209631, DOI: 10.1182/blood-2004-06-2156
G. MUTWIRIR. PONTAROLLOS. BABIUK: "Biological activity of immunostimulatory CpG ODN motif in domestic animals", VETERINARY IMMUNOPATHOLOGY, vol. 91, 2003, pages 89 - 103
HARTMANN GKRIEG AM: "Mechanism and function of a newly identified CpG DNA motif in human primary B cells", J IMMUNOL, vol. 164, no. 2, 2000, pages 944 - 953
HARTMANN, E. ET AL.: "Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer", CANCER RES, vol. 63, 2003, pages 6478 - 6487
KRIEG A MYI AKMATSON S ET AL.: "CpG motifs in bacterial DNA trigger direct B-cell activation", NATURE, vol. 374, no. 6522, 1995, pages 546 - 549, XP002587320, DOI: 10.1038/374546a0
KRIEG AM: "CpG still rocks! Update on an accidental drug", NUCLEIC ACID THER, vol. 22, no. 2, 2012, pages 77 - 89
KRIEG AM: "Therapeutic potential of Toll-like receptor 9 activation", NAT REV DRUG DISCOV, vol. 5, no. 6, 2006, pages 471 - 484, XP037925327, DOI: 10.1038/nrd2059
KRIEG AMHARTMANN GYI AK: "Mechanism of action of CpG DNA", CURT TOP MICROBIOL, vol. 247, no. 1, 2000, pages 1 - 21, XP001002250
LING SHIGAN: "Research Progress of Immunoreactive Oligodeoxynucleotide CpG", CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY, vol. 28, no. 6, 2008, pages 571 - 576
LIU SSUN WCAO Y: "Study on anti-HBV effects by antisense oligodeoxynucleotides in vitro", CHINA JOURNAL OF PREVENTIVE MEDICINE, vol. 35, no. 5, 2001, pages 338 - 340, XP008086996
LUND OSHANSEN JE: "Inhibition of HIV-1 replication by chimeric phosphorothioate oligodeoxynucleotides applied in free solution", INTERVIROLOGY, vol. 41, no. 2-3, 1998, pages 63 - 68
PASHENKOV MGOESS GWAGNER C ET AL.: "Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma", CLINICAL ONCOL OFFICIAL J AMERICAN SOCIETY CLINIC ONCOL, vol. 24, no. 36, 2006, pages 5716 - 5724, XP002585068, DOI: 10.1200/JCO.2006.07.9129
See also references of EP4130268A4
SENTI GJOHANSEN PHAUG S ET AL.: "Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial", CLINIC EXPERIM ALLERGY, vol. 39, no. 4, 2009, pages 562 - 570
SPEISER, D. E. ET AL.: "Rapid and strong human CD8(+) T cell responses to vaccination with peptide , IF A, and CPG oligodeoxynucleotide 7909", J CLIN INVEST, vol. 115, 2005, pages 739 - 746, XP009078760, DOI: 10.1172/JCI200523373
SUN S QZHANG X HTOUGH D F: "Type I interferon-mediated stimulation of T cells by CpG DNA", J. EXP MED, vol. 188, no. 12, 1998, pages 2335 - 2342, XP002164019
TOKUNAGA TYAMAMOTO HSHIMADA S ET AL.: "Antitumor activity of deoxyribonucleic acid fraction from mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity", J NATL CANCER INST, vol. 72, no. 4, 1984, pages 955 - 962, XP008038204
TOKUNAGA TYAMAMOTO SNAMBA K: "A synthetic single stranded DNA, Poly(dG, dC), induces interferon-alpha/beta and gamma, augments natural killer activity, and suppresses tumor growth", JPN J CANCER RES, vol. 79, no. 6, 1988, pages 682 - 686
TOKUNAGA TYANO OKURAMOTO E ET AL.: "Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of mycobacterium bovis BCG induce interferon and activate natural killer cells", MICROBIOL IMMUNOL, vol. 36, no. 1, 1992, pages 55 - 66
TOMOKI ITO ET AL., BLOOD, vol. 107, no. 6, 2006, pages 2423 - 2431
VAN OJIK, H. ET AL.: "Phase I/II study with CPG 7909 as adjuvant to vaccination with MAGA-3 Protein in Patients with MAGA-3 Positive tumors", ANN ONCOL, vol. 13, 2005, pages 157
XU HONGLINWANG SIQINGWANG SHIFENG: "Delineation of CpG motifs for activating human immune cells", CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY, vol. 21, no. 5, 2001, pages 471 - 475

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4332225A4 (en) * 2021-04-30 2025-11-05 Parr Biotechnology Hebei Co Ltd USE OF ARTIFICIALLY SYNTHETIC CPG SINGLE-RANK DEOXYOLIGONUCLEOTIDE IN VACCINES
CN116064548A (zh) * 2022-12-01 2023-05-05 北京吉诺卫生物科技有限公司 一种新型CpG疫苗佐剂及其应用

Also Published As

Publication number Publication date
CN113493790A (zh) 2021-10-12
JP2023519413A (ja) 2023-05-10
US20230159936A1 (en) 2023-05-25
EP4130268A1 (en) 2023-02-08
CN115413298A (zh) 2022-11-29
EP4130268A4 (en) 2024-10-02
JP7777874B2 (ja) 2025-12-01
US12600973B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
US12600973B2 (en) CpG ODN having immunoregulatory function and use thereof
CA2570786C (en) Modified cpg-containing oligonucleotide multimers in immune stimulation
Krieg Therapeutic potential of Toll-like receptor 9 activation
Uhlmann et al. Recent advances in the development of immunostimulatory oligonucleotides
KR101092043B1 (ko) 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
US7498426B2 (en) Immunostimulatory oligonucleotide multimers
EP0855184A1 (en) Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
EP3162379A1 (en) Pharmaceutical composition containing cpg oligonucleotide
JP2010001310A (ja) 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
CA2452909A1 (en) Immunostimulatory oligodeoxynucleotides
WO2010141483A2 (en) Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9
Chaung CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy
CN116200394A (zh) CpG寡聚脱氧核苷酸及其应用
CN110042103B (zh) 一种对猪具有特异性免疫刺激作用的CpG-ODN及其应用
JP2025501574A (ja) Ｃｐｇアジュバント帯状疱疹ワクチンの免疫原性
EP1657307A1 (en) Oligonucleotides that induce the secretion of GM-CSF
CN109234280B (zh) 一种梅花鹿特异性CpG寡聚脱氧核苷酸及其应用
CN110218729B (zh) 一种鸡特异性免疫活化剂CpG-ODN及其应用
Dar et al. Immunotherapeutic potential of CpG oligonucleotides in chickens
AU2004253862B2 (en) Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds
CA2551696C (en) Immunopotentiator and method for enhancing immunoactivity using the same
Domeika Porcine immunoregulatory cytokines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21778756

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022559536

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021778756

Country of ref document: EP

Effective date: 20221102

WWG Wipo information: grant in national office

Ref document number: 17915805

Country of ref document: US